Stone Summit Wealth LLC Lowers Position in Teva Pharmaceutical Industries Ltd. $TEVA

Stone Summit Wealth LLC lessened its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 15.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 11,020 shares of the company’s stock after selling 2,000 shares during the quarter. Stone Summit Wealth LLC’s holdings in Teva Pharmaceutical Industries were worth $185,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Ion Asset Management Ltd. raised its position in shares of Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after buying an additional 2,383,500 shares in the last quarter. Menora Mivtachim Holdings LTD. raised its position in shares of Teva Pharmaceutical Industries by 2.8% in the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company’s stock worth $448,640,000 after buying an additional 808,074 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company’s stock worth $404,775,000 after buying an additional 300,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock worth $338,989,000 after buying an additional 22,044,407 shares in the last quarter. Finally, Duquesne Family Office LLC raised its position in shares of Teva Pharmaceutical Industries by 65.4% in the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company’s stock worth $228,702,000 after buying an additional 5,882,350 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.3%

Shares of NYSE:TEVA opened at $18.30 on Friday. The stock’s 50-day moving average price is $17.77 and its 200-day moving average price is $16.70. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a market capitalization of $20.99 billion, a P/E ratio of -114.38, a price-to-earnings-growth ratio of 1.07 and a beta of 0.72. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries’s quarterly revenue was up .3% on a year-over-year basis. During the same period last year, the firm earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TEVA. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a “buy” rating and a $24.00 price objective on the stock. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Finally, UBS Group raised their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus target price of $25.14.

Insider Activity

In related news, insider Placid Jover sold 6,053 shares of the firm’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of the firm’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.